Is Towa Pharmaceutical (TSE:4553) Cheap On New Guidance And First Quarter Growth?

Why Towa Pharmaceutical Stock Is Back in Focus After New Guidance

Towa Pharmaceutical (TSE:4553) has drawn fresh attention after releasing new consolidated earnings guidance through March 2027 and reporting first quarter results to June 30, 2026 that show higher sales and net income versus a year earlier.

See our latest analysis for Towa Pharmaceutical.

At a share price of ¥3,790, Towa Pharmaceutical has a 1-year total shareholder return of 29.70% and a 3-year total shareholder return of 67.68%, while the 30-day share price return is down 7.90%. This suggests recent momentum has cooled after a stronger multi year run.

If this earnings driven move has you looking beyond Towa Pharmaceutical, it could be a good moment to broaden your search and check out 11 top founder-led companies

Towa Pharmaceutical now trades at a discount to both analyst targets and an estimate of fair value, even after the strong guidance and first quarter figures. Is that discount a cushion, or a warning about risks the market still sees?

Price-to-Earnings of 22.6x: Is It Justified for Towa Pharmaceutical?

Towa Pharmaceutical trades on a P/E of 22.6x, which sits above both its industry and peer averages, so the market is pricing in stronger earnings than many competitors.

The P/E multiple compares the current share price with earnings per share. For a pharmaceutical stock like Towa Pharmaceutical, it is often used as a quick way to gauge how much investors are paying for each unit of current earnings, especially where revenue and profit are already established.

At 22.6x earnings, the stock is more expensive than the JP pharmaceuticals industry average of 14.9x and also higher than the peer average of 13.6x. That said, this level is close to an estimated fair P/E of 23.4x. This is a level the market could move towards if the valuation re-rates closer to that fair ratio.

Explore the SWS fair ratio for Towa Pharmaceutical

Result: Price-to-Earnings of 22.6x (ABOUT RIGHT)

However, there are still risks that could challenge Towa Pharmaceutical, including execution on overseas expansion and any setback in earnings growth implied by its higher P/E.

Find out about the key risks to this Towa Pharmaceutical narrative.

Another View on Towa Pharmaceutical’s Valuation

The P/E comparison paints Towa Pharmaceutical as relatively expensive, yet our DCF model points in a different direction. At ¥3,790 the stock trades about 16.8% below an estimated fair value of ¥4,557.43 based on future cash flows. Is the market discounting too much, or is the model too generous?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Towa Pharmaceutical for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 25 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Weighing up both the concerns and the potential upside around Towa Pharmaceutical, it makes sense to move quickly and test the data yourself. To help with that, take a closer look at the balance of 3 key rewards and 4 important warning signs

Looking for more investment ideas beyond Towa Pharmaceutical?

If Towa Pharmaceutical is on your radar, do not stop there. The same tools that surfaced this stock can help you spot more opportunities worth your attention.

• Target steadier opportunities by checking companies that show resilience using the 57 resilient stocks with low risk scores.
• Hunt for quality at a discount with the 25 high quality undervalued stocks that highlight stocks combining strong fundamentals with attractive pricing.
• Spot potential future standouts early by reviewing the screener containing 69 high quality undiscovered gems before other investors catch on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com